Search Results
21 protocol(s) meet the specified criteria
100229Not Open *
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

100305Open  
Phase I, Open-Label, Multicenter, Dose-Escalation Study of mRNA-2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human Ox40l, for Intratumoral Injection to Patients with Advanced Malignancies

100701Open  
Open-Label, Multicenter Phase IIA Study to Evaluate the Efficacy, Safety, and Immunological Response of OBP-301, Telomerase Specific Replication-Competent Oncolytic Adenovirus in Patients with Unresectable Metastatic Melanoma

101974Open  
Phase II Study of Regn2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

101981Open  
Phase I/II Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination with Ipilimumab or Pembrolizumab in Patients with Metastatic Melanoma

102346Open  
Phase II Neoadjuvant Trial of Nivolumab in Combination with HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1A Melanoma (Neo-NivoHF10)

103138Open  
Multicenter Phase II, Adaptive, Open-Label Trial of Intratumoral pIL-12 plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment

107831Open  
Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab

108914Open  
First-In-Human, Open-Label, Dose-Escalation Trial with Expansion Cohorts to Evaluate Safety of Axl-Specific Antibody-Drug Conjugate (HuMax®-AXL-ADC) in Patients with Solid Tumors

109407Open  
Assessing Tissue Remodeling in the Skin using Skin Fluorescence Imaging (SFI)

55911Not Open *
Multicenter, Double-Blind, Placebo-Controlled, Adaptive Phase III Trial of POL-103A Polyvalent Melanoma Vaccine in Post-Resection Melanoma Patients with a High Risk of Recurrence

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

77641Open  
Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec

78383Open  
Randomized, Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib and Trametinib in BRAFV600E/K Mutant Melanoma

80350Open  
Prospective, Randomized, Blinded, Placebo-Controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) plus Yeast Cell Wall Particles (YCWP) plus Dendritic Cells (DC) Vaccine versus Unloaded YCWP plus DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence

81139Open  
PV-10 versus Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma without Distant Metastases

81405Open  
Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

82831Open  
Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

88893Open  
Phase IB Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients with Advanced Melanoma

89466Open  
Phase IB, Open-Label, Multicenter, Dose-Escalation Trial of Intratumoral Injections of SD-101 in Combination with Pembrolizumab in Patients with Metastatic Melanoma

97426Open  
Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unsectable Desmoplastic Melanoma (DM)